Evaluation of Drug-related Problems in Clinical Application of Danhong Injection Based on Granada-Ⅱ Classification
Wang Shuangyan1, Huang Dehong1, Xu Jingxiao2, Duan Hongfu3
Author information+
(1)Xiangyang Hospital of Traditional Chinese Medicine, Xiangyang 441000 , China; (2)Kunming Hospital of Traditional Chinese Medicine, Kunming 650000 , China; (3)Zhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou 450007 , China
Objective: To explore the drug-related problems (DRPs) of Danhong injection in clinical use based on Granada-Ⅱ classification, and provide references for the rational application of Danhong injection in clinic. Methods: With the help of the HIS information system of the hospital, the medical records of all inpatients who received Danhong injections in Xiangyang Hospital of Traditional Chinese Medicine, from January 1st to December 31st, 2021 were collected and sorted out. Based on the instructions of Danhong injection, relevant guidelines, expert consensus, and the guiding principles, the Granada-Ⅱ classification method was used to study and evaluate the use of Danhong injection in hospitalized patients from three aspects of necessity, effectiveness and safety. Results: Danhong injection was used by 1158 patients, of which 201 (21.76%) patients developed DRPs, and a total of 252 times of drug use occurred, including 143 drug times of DRP4 (short course of treatment), 61 drug times of DRP6 (repeated medication), 32 drug times of DRP2 (inappropriate indication), and 16 drug times of DRP5 (inappropriate vehicle selection). Most DRPS were found in the Department of Cardiology. Conclusion: When using Danhong injection, doctors should try to avoid combination with other drugs containing Danshen or safflower. Clinical pharmacists should refer to the DRPs classification criteria for clinical application of drugs based on Granada-Ⅱ classification, strengthen the special review of traditional Chinese medicine injections, and promote the rationality of clinical drug use.
Wang Shuangyan, Huang Dehong, Xu Jingxiao, Duan Hongfu.
Evaluation of Drug-related Problems in Clinical Application of Danhong Injection Based on Granada-Ⅱ Classification[J]. Chinese Pharmaceutical Affairs, 2022, 36(11): 1315-1321 https://doi.org/10.16153/j.1002-7777.2022.11.015
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 徐涛.丹红注射液临床规范化应用研究[D].郑州:河南中医学院,2014:1-91. [2] 王双艳,王春国.丹红注射液使用合理性分析[J].郑州:河南中医,2019,39(9):1376-1379. [3] Chan DC,Chen JH,Kuo HK,et al.Drug-Related Problems(DRPs)Identified from Geriatric Medication Safety Review Clinics[J].Arch Gerontol Geriatr,2012,54(1):168-174. [4] Santos H,Iglésias P,Fernández-Llimós F,et al.Segundo Consenso de Granada Sobre Problemas Relacionados Com Medicamentos.Tradu??o Intercultural de Espanhol Para Português(Europeu)[J].Acta Med Port,2004,17(1):59-66. [5] 张冠军.酮咯酸氨丁三醇注射液临床应用的药物相关问题分析[J].中国药业,2022,31(7):121-124. [6] 汪龙,程军,朱玲娜,等.基于Granada-Ⅱ分类法评价红花注射液临床应用中存在的药物相关问题[J].中国新药与临床杂志,2020,39(1):57-60. [7] 俞吉,冉烁,王茵,等.基于Granada-Ⅱ分类法对住院患者质子泵抑制剂注射剂药物相关问题的调查分析 [J].中国现代应用药学,2021,38(12):1514-1518. [8] 崔鑫,韩晟,金香兰,等.丹红注射液治疗中风(瘀血闭阻证)的临床综合评价[J].中国中药杂志,2021,46(23):6096-6104. [9] 中国中西医结合学会脑心同治专业委员会,中国医师协会中西医结合医师分会脑心同治专家委员会.丹红注射液临床应用中国专家共识[J].中国中西医结合杂志,2018,38(4):389-397. [10] 谢雁鸣,黎明全,张允岭,等.中药注射剂临床合理使用技术规范(征求意见稿)[J].中国中药杂志,2013,38(18):2930-2932. [11] 国家中医药管理局.国中医药医政发[2010]30号关于印发中成药临床应用指导原则的通知[EB/OL].(2010-06-30)[2022-04-20].http://yzs.satcm.gov.cn/gongzuodongtai/2018-03-24/3071.html. [12] 中华人民共和国国家卫生健康委员会.卫医管发[2010] 28号卫生部关于印发《医院处方点评管理规范(试行)》的通知[EB/OL].(2013-06-05)[2022-04-20].http://www.nhc.gov.cn/wjw/ywfw/201306/094ebc83dddc4 7b5a4a63ebde7224615.shtml. [13] 中华耳鼻咽喉头颈外科杂志编辑委员会,中华医学会耳鼻咽喉头颈外科学分会.突发性聋诊断和治疗指南(2015)[J].中华耳鼻咽喉头颈外科杂志,2015,50(6):443-447. [14] Jiang Y,Lian YJ.Effects of Danhong Injection on Hemodynamics and the Inflammation-Related NF-κB Signaling Pathway in Patients with Acute Cerebral Infarction[J]. Genet Mol Res,2015,14(4):16929-16937. [15] 耿银东,范萍,卢革新.丹红注射液对慢性心力衰竭患者 D-二聚体和纤维蛋白原水平的影响[J].中国医药指南,2015,13(9):207-208. [16] 李新辰,赵志刚.含木糖醇药物安全性评价及药学监护[J].药品评价,2018,15(6):3-6,26. [17] 国家食品药品监督管理局药品评价中心.总局关于修订含木糖醇注射剂说明书的公告(2017年第68号)[EB/OL].(2017-06-02)[2022-07-15].http://www.cdr-adr.org.cn/drug_1/aqjs_1/drug_aqjs_smssggg/201706/t20170602_38053.html. [18] 许先兴,杨静文,吴桂芝,等.含木糖醇注射剂临床应用现状及潜在风险分析[J].中国药物警戒,2017,14(11):680-682. [19] 杜新.临床药师在胰岛素与中药注射剂配伍中的用药监护[J].临床合理用药杂志,2013,6(23):75-76. [20] 金锐,王宇光,薛春苗,等.中成药处方点评的标准与尺度探索(二):重复用药[J].中国医院药学杂志,2015,35(7):565-570. [21] 陈倩,易丹辉,谢雁鸣,等.基于HIS“真实世界”的丹红注射液上市后临床应用分析[J].中国中药杂志,2011,36(20):2817-2820. [22] 金锐,王宇光,薛春苗,等.中成药处方点评的标准与尺度探索(八):疗程与用药时长问题[J].中国医院药学杂志,2015,35(22):1979-1985. [23] Ma Z,Sun S,Zhang C,et al.Characteristics of Drug-related Problems and Pharmacists' Interventions in A Geriatric Unit in China[J].Int J Clin Pharm,2021,43(1):270-274.